177 related articles for article (PubMed ID: 37210751)
21. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
Kim JJ; Burger EA; Regan C; Sy S
JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
[TBL] [Abstract][Full Text] [Related]
22. Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women.
Torres-Ibarra L; Lorincz AT; Wheeler CM; Cuzick J; Hernández-López R; Spiegelman D; León-Maldonado L; Rivera-Paredez B; Méndez-Hernández P; Lazcano-Ponce E; Salmerón J
Int J Cancer; 2021 May; 148(9):2264-2273. PubMed ID: 33252834
[TBL] [Abstract][Full Text] [Related]
23. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
24. Should we use risk selection tests for HPV 16 and/or 18 positive cases: Comparison of p16/Ki67 and cytology.
Mazurec K; Trzeszcz M; Mazurec M; Streb J; Halon A; Jach R
J Med Virol; 2024 Mar; 96(3):e29500. PubMed ID: 38440951
[TBL] [Abstract][Full Text] [Related]
25. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
26. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
Ting J; Smith JS; Myers ER
J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
[TBL] [Abstract][Full Text] [Related]
28. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
29. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
[TBL] [Abstract][Full Text] [Related]
31. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
32. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
33. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
Wentzensen N; Clarke MA; Bremer R; Poitras N; Tokugawa D; Goldhoff PE; Castle PE; Schiffman M; Kingery JD; Grewal KK; Locke A; Kinney W; Lorey TS
JAMA Intern Med; 2019 Jul; 179(7):881-888. PubMed ID: 31081870
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
35. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
36. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
37. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study.
Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T
Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537
[TBL] [Abstract][Full Text] [Related]
38. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
Ebisch RM; de Kuyper-de Ridder GM; Bosgraaf RP; Massuger LF; IntHout J; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Bulten J; Siebers AG; Bekkers RL; Melchers WJ
Int J Cancer; 2016 Aug; 139(3):691-9. PubMed ID: 26991464
[TBL] [Abstract][Full Text] [Related]
39. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
40. Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study.
Loopik DL; Melchers W; Vedder J; van den Brule A; Massuger L; Bekkers R; Siebers AG
BJOG; 2020 Dec; 127(13):1656-1663. PubMed ID: 32506627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]